Journal: Alzheimer's & Dementia

Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

doi: 10.1002/alz.71147

Figure Lengend Snippet: Lumipulse plasma p‐tau217 measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau

Article Snippet: Four experiments assessing the effects of varied pre‐analytical sampling conditions on relative plasma p‐tau217 concentrations were undertaken using both the Lumipulse and ALZpath assays.

Techniques: Clinical Proteomics, Derivative Assay

Journal: Alzheimer's & Dementia

Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

doi: 10.1002/alz.71147

Figure Lengend Snippet: Relative change in concentration of plasma p‐tau217 across pre‐analytical sample handling conditions: (A) pre‐centrifugation delay at RT, (B) pre‐centrifugation delay at 2 to 8°C, (C) post‐centrifugation delay, (D) number of freeze–thaw cycles, compared to the baseline condition using the ALZpath and Lumipulse assays ( n = 10 per experiment, data presented as median ± IQR, dotted lines represent the lower and upper bounds of a 10% difference threshold from the baseline condition). IQR, interquartile range; p‐tau, phosphorylated tau; RT, room temperature

Article Snippet: Four experiments assessing the effects of varied pre‐analytical sampling conditions on relative plasma p‐tau217 concentrations were undertaken using both the Lumipulse and ALZpath assays.

Techniques: Concentration Assay, Clinical Proteomics, Analytical Sample Preparation, Centrifugation

Journal: Endocrinology and Metabolism

Article Title: Reduced Sphingosine-1-Phosphate Levels Exacerbate Type 2 Diabetes Mellitus and Associated Complications in a High-Fat Diet Mouse Model

doi: 10.3803/EnM.2025.2360

Figure Lengend Snippet: Effects of 12 weeks of high-fat diet (HFD) or normal diet (ND) on oral glucose tolerance test (OGTT) and insulin responses. (A) OGTT results. (B) The plasma insulin levels were determined during the OGTT. (C) Area under the curve (AUC) of the time-blood glucose curve of OGTT. (D) AUC of the time-blood insulin curve of OGTT. (E) Glycated hemoglobin (HbA1c; %). (F) Serum triglyceride levels. (G) Serum non-esterified fatty acid (NEFA) levels in different groups of mice. KI, knock-in; WT, wild-type; NS, not significant. a P <0.05; b P <0.01; c P <0.001; d P <0.05; e P <0.001; f P <0.0001.

Article Snippet: Plasma non-esterified fatty acid (NEFA) concentrations were measured using the Randox NEFA assay kit (Randox Laboratories, Antrim, UK; #FA 115) following the manufacturer’s instructions.

Techniques: Clinical Proteomics, Knock-In